NEW YORK (GenomeWeb) – BioMérieux reported today that its third quarter revenues grew 7 percent year over year driven in part by strong growth in its molecular biology clinical applications.

For the three months ended Sept. 30, the Marcy l'Étoile, France-based in vitro diagnostics firm recorded revenues of €579.7 million ($666.3 million) compared to €540.0 million in the year-ago period. Organic growth, at constant exchange rates and scope of consolidation, was 9 percent year over year.